Encompass Health Corporation — Q1 2024 Form 10-Q
Business context and period: Unaudited results for the three months ended March 31, 2024, compared with Q1 2023. Encompass Health operates 160 inpatient rehabilitation hospitals across 37 states and Puerto Rico; this filing reports its inpatient rehabilitation business.
Key financial results
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net operating revenues | $1,316.0 million | $1,160.4 million | +13.4% |
| Income from continuing operations | $140.1 million | $114.3 million | +22.6% |
| Net income attributable to Encompass Health | $112.5 million | $87.7 million | +28.3% |
| Diluted earnings per share | $1.10 | $0.87 | Up $0.23 |
| Adjusted EBITDA | $273.0 million | $229.0 million | +19.2% |
| Net cash from operating activities | $238.8 million | $227.9 million | +$10.9 million |
Operating expenses were $1,108.5 million, up 12.9%; operating expenses declined to 84.2% of revenue from 84.6%. Derived operating margin was approximately 15.8%, versus 15.4%. Capital spending on property, equipment, and intangible assets was $139.4 million, making operating cash flow less those purchases approximately $99.4 million, compared with $128.1 million in Q1 2023.
At March 31, 2024, cash and cash equivalents were $134.4 million; restricted cash was an additional $38.3 million. Debt carrying value was $2,708.2 million, including current debt, and approximately $964 million was available under the revolving credit facility. The company reported compliance with its leverage and interest coverage covenants. Current assets were $929.8 million and current liabilities were $680.3 million.
Changes and operating drivers
- Revenue growth was attributed primarily to higher patient volumes: discharges rose 10.0%, including 6.7% same-store growth. Net patient revenue per discharge increased 2.8%, primarily from higher reimbursement rates, partly offset by patient mix.
- Occupancy increased to 76.7% from 73.4%; licensed beds rose 2.6%. Medicare represented 64.9% of revenue, versus 65.3%, while Medicare Advantage grew to 17.0% from 16.0%.
- Salaries and benefits increased 13.1% in dollars, but declined slightly as a share of revenue. Other operating expenses rose 14.6%, including higher provider taxes and development costs.
- Investing cash use increased to $129.7 million from $104.0 million, mainly reflecting greater capital purchases. Cash, cash equivalents, and restricted cash increased by $68.5 million during the quarter.
Outlook, commentary, and risks
- Management expressed optimism about longer-term demand, citing an aging population, and plans to grow through hospital development and bed additions. The filing provides no formal full-year earnings or revenue guidance.
- Management expects 2024 capital expenditures of approximately $580 million to $610 million, including $185 million to $195 million characterized as nondiscretionary. Estimated 2024 income-tax cash payments, net of refunds, are $150 million to $170 million.
- CMS’s proposed FY2025 IRF payment rule includes a 2.8% net market-basket update. Based on its analysis, the company estimates an approximately 3.0% net increase in its Medicare payment rates, effective October 1, 2024; the rule is proposed, not final.
- Medicare’s Review Choice Demonstration applies to Alabama IRFs, with expansion planned to additional states. The company said its Alabama claims validation rate exceeded the 80% threshold for the first cycle; it cannot predict the demonstration’s ultimate financial impact. The filing reports that 47 hospitals in four RCD states represent approximately 29% of its IRF Medicare claims.
- A joint-venture rehabilitation hospital in Eau Claire, Wisconsin, closed in February after its partner announced closure of the co-located acute-care hospital. Encompass Health recorded a $10.4 million impairment charge; the estimated impact on its attributable net income was $1.8 million.
- Key risks include Medicare reimbursement and audit changes, staffing availability and labor costs, regulatory compliance, litigation and potential undisclosed qui tam claims, referral and volume pressures, and debt covenant restrictions. The company reported no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether the final FY2025 CMS rule and any RCD expansion differ from the proposed or announced terms, and their effects on payment and claims collection.
- Whether volume, occupancy, and reimbursement-per-discharge trends continue, and whether labor and other operating costs remain controlled.
- Progress and timing of planned hospital openings and bed additions, and whether capital spending remains within the $580 million to $610 million estimate.
- Future cash generation, debt levels, covenant headroom, dividend decisions, and the financial effects of legal, audit, or reimbursement contingencies.